Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer.

ABSTRACT:

Introduction

Circulating tumor microemboli (CTM) are potentially important cancer biomarkers, but using them for cancer detection in early-stage disease has been assay limited. We examined CTM test performance using a sensitive detection platform to identify stage I non-small-cell lung cancer (NSCLC) patients undergoing imaging evaluation.

Methods

First, we prospectively enrolled patients during 18F-FDG PET-CT imaging evaluation for lung cancer that underwent routine phlebotomy where CTM and circulating tumor cells (CTCs) were identified in blood using nuclear (DAPI), cytokeratin (CK), and CD45 immune-fluorescent antibodies followed by morphologic identification. Second, CTM and CTC data were integrated with patient (age, gender, smoking, and cancer history) and imaging (tum

SUBMITTER: Carlsson A 

PROVIDER: S-EPMC4145608 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature